AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01544283
Drug: Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synera consists of a thin, uniform layer of a local anesthetic formulation with an integrated, oxygen-activated heating component that is intended to enhance the delivery of the local anesthetics. The drug formulation is an emulsion in which the oil phase is a eutectic mixture of lidocaine 70 mg and tetracaine 70 mg. The surface area of the entire Synera patch is approximately 50 cm2, 10 cm2 of which is active. The 40 cm2 perimeter is a medical grade adhesive. The Synera patches used in this study are the commercially available form.
Trial: NCT01112358
Drug: r-FSH
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-FSH will be administered as specified in the arm description.
Trial: NCT01112358
Drug: r-hLH
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-hLH will be administered as specified in the arm description.
Trial: NCT01208012
Drug: Victoza®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks. When arrived at the dosage of 1.8 mg daily and the dose is not tolerated by the patient, the dose of Liraglutide can be decreased.Liraglutide is injected in the subcutaneous tissue once daily
Trial: NCT01112358
Drug: r-hCG
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-hCG will be administered as specified in the arm description.
Trial: NCT01337700
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be given placebo tablets at dosing corresponding to the fixed schedule between 12.5mg and 100mg.
Trial: NCT00799383
Drug: Calcium and Vitamin D
RxNorm normalized name: Wellesse Calcium and Vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium carbonate 625mg and vitamin D 200IU will be administered, orally, twice a day for a nine-month period.
Trial: NCT01234285
Drug: heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous heparin titrated to an aPTT of 40-50 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
Trial: NCT01234285
Drug: heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous heparin titrated to an aPTT of 50-60 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
Trial: NCT01234285
Drug: heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous heparin titrated to an aPTT of 40-45 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
Trial: NCT01234285
Drug: heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5000 units subcutaneously three times a day, starting within 24 hours of ICU admission up to 6 days.
Trial: NCT04670432
Drug: Hydroxyethylrutoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg film-coated tablet
Trial: NCT00424489
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01140893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00345410
Drug: AVE1625 B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03868709
Drug: Placebo inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation is administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygendriven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
Trial: NCT01948297
Drug: Debio1347 (CH5183284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debio1347 (CH5183284) tablets for oral administration
Trial: NCT01166542
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01346852
Drug: Asthma treatment with an asthma-related medication and at least one asthma controller medication
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol.
Trial: NCT01005823
Drug: LEO 29102 cream
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice daily application for 7 days
Trial: NCT01005823
Drug: LEO 29102 placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEO 29102 placebo cream
Trial: NCT00639678
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg intravenously, double dose (day 0 and 14), Group 3
Trial: NCT00639678
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg placebo, single dose (day 0), Group 4
Trial: NCT01313793
Drug: Treatment A-B
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects to receive 3 X 15 mg tablets of the clinical formulation in first period then 1 x 45 mg tablet of the commericializable formulation in 2nd period.
Trial: NCT01313793
Drug: Treatment B-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects to receive 1 x 45 mg tablet of the commericializable formulation in first period then 3X 15 mg tablets of the clinical formulation in 2nd period.
Trial: NCT00543478
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mg, twice a day in sachets, for 8 weeks
Trial: NCT00543478
Drug: Methyl cellulose powder (low viscosity)
RxNorm normalized name: cellulose Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice a day sachets for 10 weeks
Trial: NCT01988883
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locking gelatin capsules filled with microcrystalline cellulose
Trial: NCT02902055
Drug: Neuromuscular Blocking Agents
RxNorm normalized name: NEUROMUSCULAR BLOCKING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromuscular blockae
Trial: NCT02902055
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01725451
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered topically to axillae
Trial: NCT03295721
Drug: HTX-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX 011 (bupivacaine/meloxicam), 60 mg/1.8 mg by instillation
Trial: NCT03295721
Drug: Saline Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo by instillation
Trial: NCT01520051
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 monthly intravenous infusions with saline
Trial: NCT01920737
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01920737
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01920737
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01124851
Drug: ABT-652
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm description for details
Trial: NCT04360629
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline will be given through central vein
Trial: NCT00770510
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
Trial: NCT02834611
Drug: Ceramide NanoLiposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of Ceramide NanoLiposome
Trial: NCT02808208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mL of Lactated Ringers solution topical application to the surface of the outflow vein (right next to the fistula) over a five-minute period.
Trial: NCT00971893
Drug: Oral Methylprednisolone Tablets
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Methylprednisolone tablets given as per locally approved prescribing information
Trial: NCT00571428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation solution (citrate buffered 0.9% saline solution) once a day
Trial: NCT00526968
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule, single oral dose
Trial: NCT01252069
Drug: PGL4001, placebo, drug free period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets) during 3 periods each ending with a drug free period until return of menses.
Trial: NCT01252069
Drug: PGL4001, progestin, drug free period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets) during 3 periods each ending with a drug free period until return of menses.
Trial: NCT02192346
Drug: 2.4 mg/kg α-TEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive oral α-TEA 2.4 mg/kg daily for the first 14 days of a 28 day cycle.
Trial: NCT02192346
Drug: 4.8 mg/kg α-TEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive oral α-TEA 4.8 mg/kg daily for the first 14 days of a 28 day cycle.
Trial: NCT02192346
Drug: 9.6 mg/kg α-TEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive oral α-TEA 9.6 mg/kg daily for the first 14 days of a 28 day cycle.
Trial: NCT02192346
Drug: 12 mg/kg α-TEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive oral α-TEA 12 mg/kg daily for the first 14 days of a 28 day cycle.
Trial: NCT02192346
Drug: 16.8 mg/kg α-TEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive oral α-TEA 16.8 mg/kg daily for the first 14 days of a 28 day cycle.
Trial: NCT02192346
Drug: 19.2 mg/kg α-TEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive oral α-TEA 19.2 mg/kg daily for the first 14 days of a 28 day cycle.
Trial: NCT02192346
Drug: 22.3 mg/kg α-TEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive oral α-TEA 22.3 mg/kg daily for the first 14 days of a 28 day cycle.
Trial: NCT02192346
Drug: 26.8 mg/kg α-TEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive oral α-TEA 26.8 mg/kg daily for the first 14 days of a 28 day cycle.
Trial: NCT02778919
Drug: KLH-2109
RxNorm normalized name: LINZAGOLIX CHOLINE 1 kg in 1 kg POWDER [KLH-2109 Choline]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02778919
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04449484
Drug: MEDI1341
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion over 60 minutes
Trial: NCT01626456
Drug: ALKS 9072, Low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM injection, given monthly
Trial: NCT01373970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, one tablet daily for 12 weeks
Trial: NCT01626456
Drug: ALKS 9072, High
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM injection, given monthly
Trial: NCT00813306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution, 1 single dose
Trial: NCT01652079
Drug: CRLX101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: q 14 days
Trial: NCT03316729
Drug: DS-9231
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-9231 in saline solution for intravenous infusion
Trial: NCT03316729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is matching saline solution for intravenous infusion
Trial: NCT03695926
Drug: [18F]MNI-1054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy volunteers recruited for the study will undergo a \[18F\]MNI-1054 PET scan.
Trial: NCT03629925
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA, Q3W, day1, I.V.; consecutive cycles
Trial: NCT04258033
Drug: PLB1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
Trial: NCT02677532
Drug: Sufentanil epidural bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bolus of 0.15 mcg/kg sufentanil
Trial: NCT02531204
Drug: ASP1585
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02080234
Drug: GELOX
RxNorm normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [GELOX 100]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine ：1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days
Trial: NCT00802100
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily tablets of 20 to 40 mg
Trial: NCT03614364
Drug: nanoxel
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
Trial: NCT04267822
Drug: RV521 oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each RV521 dose is four 50 mg dry powder blend capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
Trial: NCT04267822
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each placebo dose is four capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
Trial: NCT00460096
Drug: Kamada-API
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04167982
Drug: Oral conventional-dose isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional-dose isotretinoin
Trial: NCT04167982
Drug: Oral low-dose isotretinoin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: low-dose isotretinoin
Trial: NCT00092989
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of Treatment: 1 dose
Trial: NCT04377620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered BID approximately 12 hours apart
Trial: NCT01427257
Drug: Single Dose PB1023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Dose PB1023 Formulation A
Trial: NCT01427257
Drug: Single Dose PB1023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Dose PB1023 Formulation B
Trial: NCT01189604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of placebo, same infusion rates as for arm 2
Trial: NCT01189604
Drug: ICI35,868 (propofol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of propofol: initiation with 0.17 mg/kg for 3 minutes followed by maintenance with 25 µg/kg/minute
Trial: NCT01189604
Drug: ICI35,868 (propofol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of propofol: initiation with 0.33 mg/kg for 3 minutes followed by maintenance with 50 µg/kg/minute
Trial: NCT01189604
Drug: ICI35,868 (propofol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of propofol: initiation with 0.5 mg/kg for 3 minutes followed by maintenance with 75 µg/kg/minute
Trial: NCT01189604
Drug: ICI35,868 (propofol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of propofol: initiation with 0.8 mg/kg for 3 minutes followed by maintenance with 120 µg/kg/minute
Trial: NCT01189604
Drug: ICI35,868 (propofol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of propofol: initiation with 0.5 mg/kg for 1 minutes followed by maintenance with 75 µg/kg/minute
Trial: NCT01189604
Drug: ICI35,868 (propofol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of propofol: initiation with 0.5 mg/kg for 5 minutes followed by maintenance with 75 µg/kg/minute
Trial: NCT03021941
Drug: Elelyso 60 units/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients receive Elelyso 60 units/kg.
Trial: NCT02997800
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) \>20% of baseline will be treated with an initial intravenous bolus of fentanyl 50 mcg IV (50 mcg in 5 ml of normal saline). Any further increases in HR or MAP \>20% of baseline will be treated with intravenous boluses of fentanyl 25 mcg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
Trial: NCT01780077
Drug: RXI-109
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple intradermal injections of RXI-109 at incision sites
Trial: NCT01780077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple intradermal injections of placebo at incision sites
Trial: NCT01051193
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03196947
Drug: APO010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APO010 is given iv on D1, D8 and D15 followed by a one-week drug rest (cycle duration 4 weeks).
Trial: NCT04418388
Drug: PBK-1801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02571777
Drug: QVM149 150/50/160
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02571777
Drug: QVM149 150/50/80
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02571777
Drug: QMF149 150/320
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02571777
Drug: QMF149 150/160
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03287609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three injections with pre-filled auto-injector pen at day 1 and at week 4.
Trial: NCT04603456
Drug: Lacteol fort and Standardized Timothy Grass Pollen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacteol fort is a drug containing lactobacilli and the Standardized Timothy Grass Pollen includes 2 phases build up and maintenance phases.
Trial: NCT03725852
Drug: GLPG1205
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG1205 will be provided as an oral hard gelatin capsule.
Trial: NCT03725852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG1205 matching placebo will be provided as an oral hard gelatin capsule.
Trial: NCT01273181
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg/day x 2 days intravenous (IV)over 1 hour.
Trial: NCT02129348
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02327195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of placebo (PO) will be given 2 hours prior to surgery
Trial: NCT03062007
Drug: BI-CON-02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI-CON-02 prescribed as intravenous infusion once per 3 weeks. Investigational product therapy during 1 year (up to 18 cycles, duration of 21 days each).
Trial: NCT03142178
Drug: Experimental: 3VM1001 active 2g Cream 3 times daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3VM1001 2g Cream with active ingredient administered 3 times daily
Trial: NCT03142178
Drug: Experimental: 3VM1001 active 3g Cream 3 times daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3VM1001 3g Cream with active ingredient administered 3 times daily
Trial: NCT03142178
Drug: Experimental: 3VM1001 active 3g Cream 4 times daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3VM1001 3g Cream with active ingredient administered 4 times daily
Trial: NCT03142178
Drug: Placebo: 3VM1001 vehicle 2g Cream 3 times daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3VM1001 placebo 2g vehicle Cream administered 3 times daily
Trial: NCT03142178
Drug: Placebo: 3VM1001 vehicle 3g Cream 3 times daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3VM1001 placebo 3g vehicle Cream administered 3 times daily
Trial: NCT03142178
Drug: Placebo: 3VM1001 vehicle 3g Cream 4 times daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3VM1001 placebo 3g vehicle Cream administered 4 times daily
Trial: NCT00406965
Drug: HAE1 (PRO98498)
FDA approved: no
EMA approved: no
PMDA approved: no